RxDoctor Payments Data

Karen Martin

Family · Covington, TNNPI 1336139153

Payments from drug & device makers

$838in general payments, 2019–2025

Across 45 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$324
  • Lilly USA, LLC$135
  • AstraZeneca$110
  • Abbott$73
  • Pfizer$53
  • Genentech USA, Inc.$30
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$838 in reported general payments places this provider in the 60th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$135,219
Medicare patients
364
Services billed
4,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$136,587
Soliqua 100-33Insulin Glargine/Lixisenatide119$135,615
EliquisApixaban124$95,028
OzempicSemaglutide53$63,841
FarxigaDapagliflozin Propanediol62$53,438
JardianceEmpagliflozin36$45,874
RybelsusSemaglutide33$34,190
XareltoRivaroxaban39$32,361
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$30,919
LinzessLinaclotide33$28,986
TrulicityDulaglutide21$23,515
Janumet XrSitagliptin Phos/Metformin Hcl27$19,760
Synjardy XrEmpagliflozin/Metformin Hcl17$15,589
TradjentaLinagliptin18$12,533
Tresiba Flextouch U-100Insulin Degludec13$9,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$135$160,102132 claims
PfizerEliquis, Paxlovid, Premarin$53$103,246168 claims
Novo NordiskOzempic, Rybelsus$324$98,03186 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr$23$82,63784 claims
AstraZenecaFarxiga$110$53,43862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,706 family providers in Tennessee.

Other family in Covington

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →